Comparable effectiveness using flexible single-dose GnRH antagonist (cetrorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles--a prospective, randomized study.

Vlaisavljevic V, Reljic M, Lovrec VG, Kovacic B

Reproductive biomedicine online1 Oct 2003Cited by 27 (Europe PMC)

PMID14653888DOI10.1016/s1472-6483(10)61868-8PepBankPUB-14653888

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
In IVF/ICSI cycles, cetrorelix reduced mean FSH ampoules versus goserelin (25.9 versus 34.5, P < 0.01).
In plain wordsIn IVF/ICSI cycles, cetrorelix required fewer FSH ampoules than goserelin.
Peptide
Cetrorelix
Outcome
DecreaseFSH ampoules
Study
n = 460
Comparator
Goserelin protocol
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg single doseAs given in this study (human).
Measurements
Mean FSH ampoules
25.9 ampoules
Cetrorelix group
Mean FSH ampoules
34.5 ampoules
Goserelin group
Source sentences
Summary
The mean number of ampoules of FSH and the duration of stimulation was statistically significantly lower in the cetrorelix group than in the goserelin group (25.9 versus 34.5, and 9.6 versus 12.2 days, P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective randomized study compared the effectiveness of a flexible single-dose gonadotrophin-releasing hormone (GnRH) antagonist (cetrorelix) and a single-dose long GnRH agonist (goserelin) protocol for ovarian stimulation in IVF/intracytoplasmic sperm injection (ICSI) cycles.
Summary · context
Ultimately, 236 patients in the first group received a single dose of depot preparation of goserelin and 224 patients received a single 3 mg dose of cetrorelix in the late follicular phase, when the mean follicle diameter exceeded 12 mm.
Report a problemFND-1465388801
02HumanRandomized controlled trialEfficacy outcome
In IVF/ICSI cycles, goserelin required more mean FSH ampoules than cetrorelix (34.5 versus 25.9, P < 0.01).
In plain wordsIn IVF/ICSI cycles, goserelin required more FSH ampoules than cetrorelix.
Peptide
Goserelin
Outcome
IncreaseFSH ampoules
Study
n = 460
Comparator
Cetrorelix protocol
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
single dose of depot preparationAs given in this study (human).
Measurements
Mean FSH ampoules
34.5 ampoules
Goserelin group
Mean FSH ampoules
25.9 ampoules
Cetrorelix group
Source sentences
Summary
The mean number of ampoules of FSH and the duration of stimulation was statistically significantly lower in the cetrorelix group than in the goserelin group (25.9 versus 34.5, and 9.6 versus 12.2 days, P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective randomized study compared the effectiveness of a flexible single-dose gonadotrophin-releasing hormone (GnRH) antagonist (cetrorelix) and a single-dose long GnRH agonist (goserelin) protocol for ovarian stimulation in IVF/intracytoplasmic sperm injection (ICSI) cycles.
Summary · context
Ultimately, 236 patients in the first group received a single dose of depot preparation of goserelin and 224 patients received a single 3 mg dose of cetrorelix in the late follicular phase, when the mean follicle diameter exceeded 12 mm.
Report a problemFND-1465388802
03HumanRandomized controlled trialEfficacy outcome
In IVF/ICSI cycles, cetrorelix reduced stimulation duration versus goserelin (9.6 versus 12.2 days, P < 0.01).
In plain wordsIn IVF/ICSI cycles, cetrorelix reduced stimulation duration compared with goserelin.
Peptide
Cetrorelix
Outcome
DecreaseStimulation duration
Study
n = 460
Comparator
Goserelin protocol
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg single doseAs given in this study (human).
Measurements
Mean stimulation duration
9.6 days
Cetrorelix group
Mean stimulation duration
12.2 days
Goserelin group
Source sentences
Summary
The mean number of ampoules of FSH and the duration of stimulation was statistically significantly lower in the cetrorelix group than in the goserelin group (25.9 versus 34.5, and 9.6 versus 12.2 days, P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective randomized study compared the effectiveness of a flexible single-dose gonadotrophin-releasing hormone (GnRH) antagonist (cetrorelix) and a single-dose long GnRH agonist (goserelin) protocol for ovarian stimulation in IVF/intracytoplasmic sperm injection (ICSI) cycles.
Summary · context
Ultimately, 236 patients in the first group received a single dose of depot preparation of goserelin and 224 patients received a single 3 mg dose of cetrorelix in the late follicular phase, when the mean follicle diameter exceeded 12 mm.
Report a problemFND-1465388803
04HumanRandomized controlled trialEfficacy outcome
In IVF/ICSI cycles, goserelin required longer stimulation than cetrorelix (12.2 versus 9.6 days, P < 0.01).
In plain wordsIn IVF/ICSI cycles, goserelin required longer stimulation than cetrorelix.
Peptide
Goserelin
Outcome
IncreaseStimulation duration
Study
n = 460
Comparator
Cetrorelix protocol
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
single dose of depot preparationAs given in this study (human).
Measurements
Mean stimulation duration
12.2 days
Goserelin group
Mean stimulation duration
9.6 days
Cetrorelix group
Source sentences
Summary
The mean number of ampoules of FSH and the duration of stimulation was statistically significantly lower in the cetrorelix group than in the goserelin group (25.9 versus 34.5, and 9.6 versus 12.2 days, P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective randomized study compared the effectiveness of a flexible single-dose gonadotrophin-releasing hormone (GnRH) antagonist (cetrorelix) and a single-dose long GnRH agonist (goserelin) protocol for ovarian stimulation in IVF/intracytoplasmic sperm injection (ICSI) cycles.
Summary · context
Ultimately, 236 patients in the first group received a single dose of depot preparation of goserelin and 224 patients received a single 3 mg dose of cetrorelix in the late follicular phase, when the mean follicle diameter exceeded 12 mm.
Report a problemFND-1465388804
05HumanRandomized controlled trialEfficacy outcome
In IVF/ICSI cycles, retrieved oocytes were similar with cetrorelix and goserelin (6.7 +/- 4.5 versus 7.2 +/- 4.6, NS).
In plain wordsIn IVF/ICSI cycles, egg retrieval was similar with cetrorelix and goserelin.
Peptide
Cetrorelix
Outcome
No significant changeOocytes retrieved
Study
n = 460
Comparator
Goserelin protocol
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg single doseAs given in this study (human).
Measurements
Mean oocytes retrieved
6.7 oocytes
Cetrorelix group, SD 4.5
Mean oocytes retrieved
7.2 oocytes
Goserelin group, SD 4.6
Source sentences
Summary
The mean number of oocytes retrieved was similar (6.7 +/- 4.5 versus 7.2 +/- 4.6, NS).
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective randomized study compared the effectiveness of a flexible single-dose gonadotrophin-releasing hormone (GnRH) antagonist (cetrorelix) and a single-dose long GnRH agonist (goserelin) protocol for ovarian stimulation in IVF/intracytoplasmic sperm injection (ICSI) cycles.
Summary · context
Ultimately, 236 patients in the first group received a single dose of depot preparation of goserelin and 224 patients received a single 3 mg dose of cetrorelix in the late follicular phase, when the mean follicle diameter exceeded 12 mm.
Report a problemFND-1465388805
06HumanRandomized controlled trialEfficacy outcome
In IVF/ICSI cycles, goserelin and cetrorelix produced similar numbers of retrieved oocytes.
In plain wordsIn IVF/ICSI cycles, egg retrieval was similar with goserelin and cetrorelix.
Peptide
Goserelin
Outcome
No significant changeOocytes retrieved
Study
n = 460
Comparator
Cetrorelix protocol
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
single dose of depot preparationAs given in this study (human).
Measurements
Mean oocytes retrieved
7.2 oocytes
Goserelin group, SD 4.6
Mean oocytes retrieved
6.7 oocytes
Cetrorelix group, SD 4.5
Source sentences
Summary
The mean number of oocytes retrieved was similar (6.7 +/- 4.5 versus 7.2 +/- 4.6, NS).
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective randomized study compared the effectiveness of a flexible single-dose gonadotrophin-releasing hormone (GnRH) antagonist (cetrorelix) and a single-dose long GnRH agonist (goserelin) protocol for ovarian stimulation in IVF/intracytoplasmic sperm injection (ICSI) cycles.
Summary · context
Ultimately, 236 patients in the first group received a single dose of depot preparation of goserelin and 224 patients received a single 3 mg dose of cetrorelix in the late follicular phase, when the mean follicle diameter exceeded 12 mm.
Report a problemFND-1465388806
07HumanRandomized controlled trialEfficacy outcome
In IVF/ICSI cycles, fertilization, blastulation and blastocyst transfer rates were similar with cetrorelix and goserelin.
In plain wordsIn IVF/ICSI cycles, fertilization, blastulation and blastocyst transfer rates were similar with cetrorelix and goserelin.
Peptide
Cetrorelix
Outcome
Direction not reportedFertilization, blastulation and blastocyst transfer rates
Study
n = 460
Comparator
Goserelin protocol
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg single doseAs given in this study (human).
Source sentences
Summary
Similar results were observed in fertilization rates, blastulation rates and blastocyst transfer rates in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective randomized study compared the effectiveness of a flexible single-dose gonadotrophin-releasing hormone (GnRH) antagonist (cetrorelix) and a single-dose long GnRH agonist (goserelin) protocol for ovarian stimulation in IVF/intracytoplasmic sperm injection (ICSI) cycles.
Summary · context
Ultimately, 236 patients in the first group received a single dose of depot preparation of goserelin and 224 patients received a single 3 mg dose of cetrorelix in the late follicular phase, when the mean follicle diameter exceeded 12 mm.
Report a problemFND-1465388807
08HumanRandomized controlled trialEfficacy outcome
In IVF/ICSI cycles, fertilization, blastulation and blastocyst transfer rates were similar with goserelin and cetrorelix.
In plain wordsIn IVF/ICSI cycles, fertilization, blastulation and blastocyst transfer rates were similar with goserelin and cetrorelix.
Peptide
Goserelin
Outcome
Direction not reportedFertilization, blastulation and blastocyst transfer rates
Study
n = 460
Comparator
Cetrorelix protocol
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
single dose of depot preparationAs given in this study (human).
Source sentences
Summary
Similar results were observed in fertilization rates, blastulation rates and blastocyst transfer rates in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective randomized study compared the effectiveness of a flexible single-dose gonadotrophin-releasing hormone (GnRH) antagonist (cetrorelix) and a single-dose long GnRH agonist (goserelin) protocol for ovarian stimulation in IVF/intracytoplasmic sperm injection (ICSI) cycles.
Summary · context
Ultimately, 236 patients in the first group received a single dose of depot preparation of goserelin and 224 patients received a single 3 mg dose of cetrorelix in the late follicular phase, when the mean follicle diameter exceeded 12 mm.
Report a problemFND-1465388808
09HumanRandomized controlled trialEfficacy outcome
In IVF/ICSI cycles, clinical pregnancy per cycle was 31.9% with cetrorelix versus 34.3% with goserelin, without a significant difference.
In plain wordsClinical pregnancy per cycle was 31.9% with cetrorelix versus 34.3% with goserelin, without a significant difference.
Peptide
Cetrorelix
Outcome
No significant changeClinical pregnancy per cycle
Study
n = 460
Comparator
Goserelin protocol
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg single doseAs given in this study (human).
Measurements
Clinical pregnancy rate per cycle
31.9 % per cycle
Cetrorelix group
Clinical pregnancy rate per cycle
34.3 % per cycle
Goserelin group
Source sentences
Summary
Clinical pregnancy and delivery rates per cycle were higher in the goserelin group (34.3 and 30.1%) than in the cetrorelix group (31.9 and 28.3%), but the differences were not statistically significant.
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective randomized study compared the effectiveness of a flexible single-dose gonadotrophin-releasing hormone (GnRH) antagonist (cetrorelix) and a single-dose long GnRH agonist (goserelin) protocol for ovarian stimulation in IVF/intracytoplasmic sperm injection (ICSI) cycles.
Summary · context
Ultimately, 236 patients in the first group received a single dose of depot preparation of goserelin and 224 patients received a single 3 mg dose of cetrorelix in the late follicular phase, when the mean follicle diameter exceeded 12 mm.
Report a problemFND-1465388809
10HumanRandomized controlled trialEfficacy outcome
In IVF/ICSI cycles, clinical pregnancy per cycle was 34.3% with goserelin versus 31.9% with cetrorelix, without a significant difference.
In plain wordsClinical pregnancy per cycle was 34.3% with goserelin versus 31.9% with cetrorelix, without a significant difference.
Peptide
Goserelin
Outcome
No significant changeClinical pregnancy per cycle
Study
n = 460
Comparator
Cetrorelix protocol
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
single dose of depot preparationAs given in this study (human).
Measurements
Clinical pregnancy rate per cycle
34.3 % per cycle
Goserelin group
Clinical pregnancy rate per cycle
31.9 % per cycle
Cetrorelix group
Source sentences
Summary
Clinical pregnancy and delivery rates per cycle were higher in the goserelin group (34.3 and 30.1%) than in the cetrorelix group (31.9 and 28.3%), but the differences were not statistically significant.
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective randomized study compared the effectiveness of a flexible single-dose gonadotrophin-releasing hormone (GnRH) antagonist (cetrorelix) and a single-dose long GnRH agonist (goserelin) protocol for ovarian stimulation in IVF/intracytoplasmic sperm injection (ICSI) cycles.
Summary · context
Ultimately, 236 patients in the first group received a single dose of depot preparation of goserelin and 224 patients received a single 3 mg dose of cetrorelix in the late follicular phase, when the mean follicle diameter exceeded 12 mm.
Report a problemFND-1465388810
11HumanRandomized controlled trialEfficacy outcome
In IVF/ICSI cycles, delivery per cycle was 28.3% with cetrorelix versus 30.1% with goserelin, without a significant difference.
In plain wordsDelivery per cycle was 28.3% with cetrorelix versus 30.1% with goserelin, without a significant difference.
Peptide
Cetrorelix
Outcome
No significant changeDelivery per cycle
Study
n = 460
Comparator
Goserelin protocol
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg single doseAs given in this study (human).
Measurements
Delivery rate per cycle
28.3 % per cycle
Cetrorelix group
Delivery rate per cycle
30.1 % per cycle
Goserelin group
Source sentences
Summary
Clinical pregnancy and delivery rates per cycle were higher in the goserelin group (34.3 and 30.1%) than in the cetrorelix group (31.9 and 28.3%), but the differences were not statistically significant.
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective randomized study compared the effectiveness of a flexible single-dose gonadotrophin-releasing hormone (GnRH) antagonist (cetrorelix) and a single-dose long GnRH agonist (goserelin) protocol for ovarian stimulation in IVF/intracytoplasmic sperm injection (ICSI) cycles.
Summary · context
Ultimately, 236 patients in the first group received a single dose of depot preparation of goserelin and 224 patients received a single 3 mg dose of cetrorelix in the late follicular phase, when the mean follicle diameter exceeded 12 mm.
Report a problemFND-1465388811
12HumanRandomized controlled trialEfficacy outcome
In IVF/ICSI cycles, delivery per cycle was 30.1% with goserelin versus 28.3% with cetrorelix, without a significant difference.
In plain wordsDelivery per cycle was 30.1% with goserelin versus 28.3% with cetrorelix, without a significant difference.
Peptide
Goserelin
Outcome
No significant changeDelivery per cycle
Study
n = 460
Comparator
Cetrorelix protocol
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
single dose of depot preparationAs given in this study (human).
Measurements
Delivery rate per cycle
30.1 % per cycle
Goserelin group
Delivery rate per cycle
28.3 % per cycle
Cetrorelix group
Source sentences
Summary
Clinical pregnancy and delivery rates per cycle were higher in the goserelin group (34.3 and 30.1%) than in the cetrorelix group (31.9 and 28.3%), but the differences were not statistically significant.
2 context sentences(design, population, supporting numbers)
Summary · context
This prospective randomized study compared the effectiveness of a flexible single-dose gonadotrophin-releasing hormone (GnRH) antagonist (cetrorelix) and a single-dose long GnRH agonist (goserelin) protocol for ovarian stimulation in IVF/intracytoplasmic sperm injection (ICSI) cycles.
Summary · context
Ultimately, 236 patients in the first group received a single dose of depot preparation of goserelin and 224 patients received a single 3 mg dose of cetrorelix in the late follicular phase, when the mean follicle diameter exceeded 12 mm.
Report a problemFND-1465388812

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 2
27 Oct 2026, 16:35 UTC
Study data updated · source update from Europe PMC
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Comparable effectiveness using flexible single-dose GnRH antagonist (cetrorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles--a prospective, randomized study.

Summary

Results from this study12

Version history

Subjects

Publication types

MeSH terms